Benlysta belimumab for injection, for intravenous use and subcutaneous use. Benlysta package insert pdf keyword after analyzing the system lists the list of keywords related and the list of websites with related content, in addition you can see which keywords most interested customers on the this website. Do not put the medicine back into the refrigerator. The package leaflet should be provided to the patient each time benlysta is administered. Precertification of belimumab benlysta is required of all aetna participating providers and members in applicable plan designs. Benlysta should not be infused concomitantly in the same intravenous line with other agents. Common and rare side effects for benlysta intravenous. Gsk receives chmp positive opinion for selfinjectable formulation of benlysta for systemic lupus erythematosus. Gsk receives chmp positive opinion for selfinjectable.
Efficacy and safety of belimumab in patients with active. Other drugs may be given before this medicine belimumab vials to help avoid side effects. It is approved in the united states, canada, and europe to treat systemic lupus erythematosus sle. Benlysta belimumab for injection, for intravenous use only. Do not use belimumab if it has been left at room temperature longer than 12 hours. However, serologically active sle patients responded significantly better to belimumab therapy plus soc than to soc alone. Listing a study does not mean it has been evaluated by the u. Belimumab is a monoclonal antibody that affects the actions of the bodys immune system. The effect of belimumab on the reduction of sle disease activity or flares was not significant. Belimumab treatment holiday and treatment restart study in lupus patients the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. This emedtv segment explains what this means and offers information on what the drugs manufacturer recommends and how this product performed in animal studies. Belimumab is produced by recombinant dna technology in a murine cell ns0 expression system. Benlysta package insert pdf keyword found websites. Belimumab trade name benlysta, previously known as lymphostatb is a human monoclonal antibody that inhibits bcell activating factor baff, also known as blymphocyte stimulator blys.
For precertification of belimumab benlysta, call 866 7527021, or fax 866 2673277. The recommended dosage is 200 mg once weekly given as a subcutaneous injection in the abdomen or thigh. Efficacy and safety of subcutaneous belimumab in antidouble. Learn about drug imprint, side effects, uses treating, dosage, interaction, overdose, and warnings. Belimumab benlysta pregnancy registry full text view. Early disease and low baseline damage predict response to. The solution should be clear to opalescent and colorless to pale yellow. Belimumab is a human igg1 neutralizing monoclonal antibody against blymphocyte stimulating factor also known as blymphocyte stimulator blys. Benlysta belimumab is the first and only approved treatment designed for lupus sle or systemic lupus erythematosus. Word for the web doesnt let you insert objects, such as pdfs, into a document. In addition, pregnancy and infant outcomes will also be collected for pregnancies in women with sle. Fda clears selfinjectable belimumab benlysta for sle. Benlysta isindicated for the treatment of adult patients with active, autoantibody positive systemic lupus erythematosus who are receiving standard therapy. However, you can edit the pdf itself in word for the web, which lets you update the pdf s content, or copy and paste content from the pdf into a word document.
When belimumab was approved in march 2011, the indication section of the package insert stated and still stands when most recently revised in april 2014. The indications below including fdaapproved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. Belimumab package insert pdf belimumab has been studied in a limited number of sle patients with renal syringe are provided at the end of the package leaflet see stepbystep. Ten has been reported for rituximab see rituximab package insert. Benlysta belimumab is indicated for the treatment of patients aged 5 years and older with active, autoantibodypositive, systemic lupus erythematosus sle who are receiving standard therapy. Belimumab is contraindicated in patients with active infection. Systemic lupus erythematosus sle is a chronic inflammatory disorder that is driven by autoantibodies that target multiple organ systems. Belimumab is used to treat active systemic lupus erythematosus in adults. This emedtv article explains the uses of belimumab in greater detail, with information on who can use this drug and what type of lupus it can treat. What are the possible side effects of belimumab benlysta, benlysta autoinjector. The efficacy and safety of iv belimumab has been demonstrated in. What should i discuss with my healthcare provider before using belimumab.
Belimumab is the only approved biological agent for the treatment of systemic lupus erythematosus sle. Biologic activity and safety of belimumab, a neutralizing antiblymphocyte stimulator blys monoclonal antibody. Among patients treated with belimumab 10mgkg in addition to standard therapy, 58% had selenasledai scores reduced by. Blymphocyte stimulator blys and its receptors on bcell subsets play an important role in autoimmune bcell development and sle pathogenesis. Benlysta belimumab side effects, images, uses, dosage. By binding blys, benlysta allows more b cells to undergo the normally occurring process of apoptosis, which inhibits the survival of b cells, including autoreactive b cells and reduces the differentiation of b cells into immunoglobulin. Highlights of prescribing information these highlights do not. The authors concluded that belimumab was biologically active and welltolerated. Call your pharmacist if there are any problems with the package or the syringe and do not inject the medication. Protect from light and do not shake or heat the medicine.
The feature directory provides a convenient quick reference list for 12 features. Evidencebased recommendations on belimumab benlysta as an addon treatment for active autoantibodypositive systemic lupus erythematosus in adults there is a managed access agreement, which sets out the conditions for availability of belimumab guidance development process. A read is counted each time someone views a publication summary such as the title, abstract, and list of authors, clicks on a figure, or views or downloads the fulltext. April 2012 each of the bliss trials were threearm trials belimumab 10 mgkg, belimumab 1 mgkg and placebo, only results for the 10 mgkg belimumab dose were presented in the manufacturers. You may inject belimumab injection on the front of the thighs or anywhere on your stomach except your navel belly button and the area 2 inches around it. Delayedtype, nonacute hypersensitivity reactions have also been observed and. Blymphocyte stimulator blys and its receptors on bcell subsets play an important role in autoimmune bcell development. If a new infection develops, consider interrupting belimumab therapy and monitor the patient closely. Belimumab treatment holiday and treatment restart study. Cases of stevensjohnson syndrome sjs and ten, some fatal, have been reported when treanda was administered concomitantly with allopurinol and other medications known to cause these syndromes. Belimumab benlysta pregnancy registry the belimumab benlysta pregnancy registry is a prospective cohort study that enrolls women with systemic lupus erythematosus sle who have been given exposed to commerciallysupplied belimumab within the 4 months prior to andor during pregnancy. Benlysta belimumab for injection, for intravenous use only initial u.
Benlysta is a blymphocyte stimulator blys specific inhibitor indicated for the treatment of adult patients with active, autoantibodypositive, systemic lupus erythematosus who are receiving standard therapy. Most likely, the feature directory on your voice terminal has been completed by. Belimumab treatment holiday and treatment restart study in. First approved lupus treatment option benlysta belimumab. Learn about benlysta belimumab, a treatment option that may be right for you.
An indirect comparison of intravenous and subcutaneous. Belimumab is a monoclonal antibody against soluble blymphocyte stimulator, an essential growth factor for bcell maturation and activation, which was approved by the us fda in 2011 for patients. Sle is an inflammatory autoimmune disease, which means that the bodys immune system attacks its own tissues and causes inflammation. Efficacy and safety of the subcutaneous belimumab in systemic lupus erythematosus. Learn about ocrevus ocrelizumab, a prescription medicine used to treat adults with relapsing or primary progressive multiple sclerosis. It is given as an infusion into a vein over a period of time. Persons with disabilities having problems accessing the pdf files below may call 301 7963634 for assistance. Use this medicine belimumab vials as ordered by your doctor.
Belimumab definition of belimumab by medical dictionary. Use caution when considering belimumab in patients with chronic infections. This may help to protect healthy cells from damage. Signs and symptoms of inflammation may be lessened due to suppression from belimumab. Parts of the body affected by sle include the heart, skin, joints, kidneys, lungs, and brain. Belimumab, a prescription medication, is approved for the treatment of lupus. Overview belimumab for treating active autoantibody. Benlysta 120 mg powder for concentrate for solution for infusion.
This global belimumab pregnancy registry will collect prospective data on pregnancies and pregnancy outcomes on a voluntary basis in women with systemic lupus erythematosus sle who have received commercially supplied belimumab within the 4 months prior to andor during pregnancy. Benlysta belimumab for injection is a sterile, white to offwhite, preservative. Site of care utilization management policy applies to belimumab benlysta. Based on the clinical trials, belimumab appears to be generally well tolerated, although safety concerns were raised for hypersensitivity, infections, depression, and overall mortality. The us food and drug administration fda has approved a new subcutaneous formulation of belimumab benlysta. Take the package out of the refrigerator to let the medicine reach room temperature for 30 minutes before injecting your dose. Belimumab side effects, dosage, interactions drugs. Benlysta should be administered by healthcare providers prepared to manage anaphylaxis see warnings and precautions 5. Benlysta 120 mg powder for concentrate for solution for. Benlysta belimumab for injection, for intravenous use.
Find information about common, infrequent and rare side effects of benlysta intravenous. Article pdf available in drug development research 727 november 2011 with 195 reads. Benlysta 400 mg powder for concentrate for solution for infusion. Per package insert, the efficacy of benlysta has not been evaluated in patients with severe. Belimumab is used with other medications to treat certain types of systemic lupus erythematosus sle or lupus. Highlights of prescribing information these highlights do. Benlysta belimumab is indicated for the treatment of adult patients with active, autoantibodypositive, systemic lupus erythematosus sle who are receiving standard therapy. Fda questions safety, efficacy of belimumab medpage today.
Vision impaired people having problems accessing certain pages of a pdf file may call 301 7963634 for assistance. Talk to your doctor about benlysta for more information. Type 1 glass vials 5 ml, sealed with a siliconised chlorobutyl rubber stopper and a flipoff aluminum seal containing 120 mg of powder. Xgeva is indicated for the prevention of skeletalrelated events in patients with multiple myeloma and in patients with bone metastases from solid tumors. Successful treatment of a mycophenolate mofetilrefractory. Pdf belimumab therapy for systemic lupus erythematosus and. Belimumab assessment of safety in sle full text view. Limitations of use the efficacy of benlysta has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Monoclonal antibodies are made to target and destroy only. Final appraisal determination belimumab for the treatment of active autoantibodypositive systemic lupus erythematosus issue date. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus. Study participants receive standard therapy for sle in addition to receiving the study drug, either placebo no active medicine or belimumab. When belimumab was approved in march 2011, the indication section of the package insert stated and still stands when most recently revised. Belimumab significantly improved the response rate, reduced disease activity and severe flares, and was well tolerated.
Welcome to the leading independent provider of fda approved medication information, delivering the latest package inserts and product labels directly from the fda repository in an easytoread format. In addition, pregnancy and infant outcomes will also be collected for pregnancies in women. The belimumab benlysta pregnancy registry is a prospective cohort study that enrolls women with systemic lupus erythematosus sle who have been given exposed to commerciallysupplied belimumab within the 4 months prior to andor during pregnancy. Highlights of prescribing information these highlights do not include all the information needed to use benlysta safely and effectively. Belimumab is a synthetic manmade injectable antibody that reduces the activity of immune cells called bcells in patients with systemic lupus erythematosus.
The fda has given benlysta belimumab a pregnancy category c rating. Belimumab benlysta is a targeted, human monoclonal antibody that binds to soluble b lymphocyte stimulator blys. Jan 17, 2020 belimumab is produced by recombinant dna technology in a murine cell ns0 expression system. What is the most important information i should know about belimumab benlysta, benlysta autoinjector. Merrill jt1, ginzler em, wallace dj, mckay jd longterm safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Belimumab showed encouraging results in openlabel phase ii study of patients with primary sjogrens syndrome. Belimumab for the treatment of active autoantibody. The diluted solution of benlysta should be administered by intravenous infusion over a period of 1 hour. Objective to investigate the efficacy and safety of belimumab. Nov 09, 2018 belimumab is a monoclonal antibody that affects the actions of the bodys immune system. Avaya 6402d manual pdf the feature directory provides a convenient quick reference list for 12 features. August 11, 2019 august 11, 2019 leave a comment on avaya 6402d manual pdf. Feb 03, 2020 benlysta belimumab for injection, for intravenous use and subcutaneous use. Most likely, the feature directory on your voice terminal has been.
908 1223 989 1519 618 925 33 649 991 634 612 1349 1248 989 758 913 159 734 29 428 1450 1239 1592 1536 1472 774 246 437 808 897 1535 530 1144 1542 1581 1431 429 1131 282 525 996 1315 1406 1062 422 335